Patents by Inventor Joerg-Christian Heinrich

Joerg-Christian Heinrich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds with thymine skeleton for use in medicine
    Patent number: 11214564
    Abstract: The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 4, 2022
    Assignee: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Michael Schroeder, Yixin Zhang, Jörg-Christian Heinrich, Joachim Haupt, Petra Lennig
  • NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE
    Publication number: 20210130328
    Abstract: The present invention relates to novel compounds as new chemical entities with thymine skeleton, these compounds for use as in medicine, especially in the treatment of carcinoma, HSP27-associated diseases and cystic fibrosis; and a pharmaceutical product containing at least one of these compounds. Finally, a method of production of that novel compounds is presented. General formula of these compounds is formula (I): as further defined in claim 1.
    Type: Application
    Filed: November 3, 2020
    Publication date: May 6, 2021
    Applicant: TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Michael SCHROEDER, Yixin ZHANG, Jörg-Christian HEINRICH, Joachim HAUPT, Petra LENNIG
  • Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
    Patent number: 10940150
    Abstract: The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: March 9, 2021
    Assignee: Technische Universitaet Dresden
    Inventors: Michael Schroeder, Yixin Zhang, Joerg-Christian Heinrich, Joachim Haupt, Sainitin Donakonda, Petra Lennig
  • THYMINE DERIVATIVES AND QUINAZOLINE-DIONE DERIVATIVES FOR THE INHIBITION OF HSP27
    Publication number: 20180207160
    Abstract: The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.
    Type: Application
    Filed: July 28, 2015
    Publication date: July 26, 2018
    Applicant: TECHNISCHE UNIVERSITAET DRESDEN
    Inventors: Michael Schroeder, Yixin Zhang, Joerg-Christian Heinrich, Joachim Haupt, Sainitin Donakonda, Petra Lennig
  • EFFICIENT INHIBITION OF HSP27
    Publication number: 20170216297
    Abstract: The present invention relates to novel HSP27 inhibitors, in particular purine derivatives according to general formula (I) or (II) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP2.
    Type: Application
    Filed: July 28, 2015
    Publication date: August 3, 2017
    Applicant: TECHNISCHE UNIVERSITAET DRESDEN
    Inventors: Michael Schroeder, Yixin Zhang, Joerg-Christian Heinrich, Joachim Haupt, Sainitin Donakonda, Petra Lennig
  • URACIL DERIVATIVES AND USE THEREOF
    Publication number: 20110166096
    Abstract: Disclosed are uracil derivatives of the formula (I): wherein R1, R2, R3, and X are as defined herein, and use thereof as therapeutic agents. The uracil derivatives are used in particular together with a cytostatic agent for suppressing or reducing resistance building up on cytostatic treatment.
    Type: Application
    Filed: June 25, 2009
    Publication date: July 7, 2011
    Applicant: RESPROTECT GMBH
    Inventors: Rudolf Fahrig, Kurt Eger, Martin Führer, Nicole Heinze, Matthias Klemm, Jörg-Christian Heinrich
  • NUCLEOSIDES FOR SUPPRESSING OR REDUCING THE DEVELOPMENT OF RESISTANCE IN CYTOSTATIC THERAPY
    Publication number: 20100227834
    Abstract: The invention relates to special nucleosides, for example, a nucleoside of the formula I, wherein R1-R5 are as described herein, and also to drugs which contain these nucleosides. Furthermore, the invention relates to the use of such nucleosides in a method for suppressing or reducing the formation of resistance in the case of cytostatic treatment of a cancer patient.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 9, 2010
    Applicant: RESprotech GmbH
    Inventors: Rudolf Fahrig, Dieter Lohmann, Andreas Rolfs, Henrik Dieks, Janek Teubner, Jörg-Christian Heinrich
  • Use of 5-substituted nucleosides for reinforcing the apoptotic effect of cytostatic drugs
    Patent number: 7713948
    Abstract: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
    Type: Grant
    Filed: November 20, 2003
    Date of Patent: May 11, 2010
    Assignee: Resprotect GmbH
    Inventors: Rudolf Fahrig, Joerg-Christian Heinrich, Georg Krupitza
  • METHOD OF TREATING CANCER BY ADMINISTRATION OF 5-SUBSTITUTED NUCLEOSIDES
    Publication number: 20090068286
    Abstract: The invention relates to methods of administration of at least one overexpression inhibitor of DNA repair genes and/or oncogenes (e.g., (E)-5-(2-bromovinyl)-2?-deoxyuridine (BVDU), or a prodrug, or salt thereof) to increase the cytotoxic effect of a cytostatic or cytotoxic chemotherapeutic agent during and/or after chemotherapy, e.g., in the treatment of cancer.
    Type: Application
    Filed: September 11, 2007
    Publication date: March 12, 2009
    Applicant: RESprotect, GmbH
    Inventors: Rudolf FAHRIG, Joerg-Christian Heinrich
  • Use of 5-substituterd nucleosides for reinforcing the apoptotic effect of cytostatic drugs
    Publication number: 20060178338
    Abstract: The invention relates to the use of at least one overexpression inhibitor of DNA repair genes and oncogenes for producing a drug to increase the apoptotic effect of cytostatics after chemotherapy.
    Type: Application
    Filed: November 20, 2003
    Publication date: August 10, 2006
    Inventors: Rudolf Fahrig, Joerg-Christian Heinrich, Georg Krupitza